Clear cell ovarian cancer (OCCC), the second-most common type of epithelial ovarian cancer, is associated with poor prognosis and widespread resistance to standard chemotherapy, and a dearth of other suitable treatment options. Recent work has reported that glycolysis and glycogenolysis are both genetic and phenotypic hallmarks of OCCC. Herein we have sought to assess whether this can be targeted with the glucose analog 2-deoxy-d-glucose (2-DG). It was hypothesised that low dose 2-DG can act synergistically with standard of care chemotherapy carboplatin in an OCCC setting. A combined therapy of 2-DG and the standard chemotherapy carboplatin was investigated across a panel of cell lines in vitro, as well as both cell-line xenografts and patient-derived xenografts in vivo. The combined therapy of low-dose 2-DG alongside carboplatin showed synergistic efficacy in vitro, and this effect was shown to be mediated by cellular glycogen and prosurvival pathways. We also report that combining low-dose 2-DG with carboplatin in vivo in intra-peritoneal cell-line xenograft and patient-derived xenograft models showed a marked reduction in tumour yield compared to control and monotherapies. Hence, our study provides a preclinical justification for combining 2-DG with carboplatin as a therapy for clear cell ovarian cancer.